Acasti Pharma Investor Presentation November 2022

Acasti Pharma is a specialty pharmaceutical company developing novel formulations and drug delivery technologies for rare and orphan diseases. The company's lead clinical assets have received Orphan Drug Designation with potential for extended market exclusivity in the US and EU. With approximately $38.4 million in cash and a 505(b)(2) regulatory pathway, Acasti targets an estimated $3 billion addressable market for its three lead programs.